Rhodiola rosea L. and Alzheimer's Disease: From Farm to Pharmacy
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Rhodiola rosea L. (roseroot) is a common member of the family Crassulaceae, known as one of the most important popular medicinal plants in the northern region of Europe. The roots of R. rosea possess a wide range of pharmacological activities such as antioxidant, antiinflammatory, anticancer, cardioprotective, and neuroprotective effects that are because of the presence of different phytochemicals such as phenols and flavonoids. In addition, the presence of salidroside, rosavins, and p‐tyrosol are responsible for its beneficial effects for the treatment of on depression, fatigue, and cognitive dysfunction. A plethora of studies report that R. rosea has potent neuroprotective effects through the suppression of oxidative stress, neuroinflammation, and excitotoxicity in brain tissues and antagonism of oncogenic p21‐activated kinase. However, to our knowledge, no review articles have been published addressing the neuroprotective effects of R. rosea. Therefore, the present article aims at critically reviewing the available literature on the beneficial effects of R. rosea on as a therapeutic strategy for the treatment of Alzheimer's disease and other neurodegenerative diseases where oxidative stress plays a major role in disease development and progression. We also discuss the cultivation, phytochemistry, clinical impacts, and adverse effects of R. rosea to provide a broader insight on the therapeutic potential for this plant. Copyright © 2016 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 1×
“Microglial cells, the resident immune cells of the brain, have been shown to be recruited to AD-associated Aβ plaques and in close proximity to neurofibrillary tangles (Rogers et al., 1988; Griffin et al., 1989).”
BackgroundLindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261
MICROGLIA AS MEDIATORS OF INFLAMMATORY AND DEGENERATIVE DISEASES
González-Scarano, F., & Baltuch, G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.219 · Cited by 984 · cited 1×
“Several studies have demonstrated that activated microglia can produce significant quantities of inflammatory mediators capable of releasing large amounts of ROS, nitric oxide (NO), and proinflammatory cytokines such as TNF-α, interleukin-1β (IL-1β), and interleukin-6 (IL-6), culminating in neuronal cell death (Gonzal…”
BackgroundPhosphatase‐mediated crosstalk between MAPK signaling pathways in the regulation of cell survival
Junttila, M. R., Li, S., & Westermarck, J. (2008) · The FASEB Journal · doi:10.1096/fj.06-7859rev · Cited by 826
Dendritic Spine Pathology: Cause or Consequence of Neurological Disorders?
Fiala, J. C., Spacek, J., & Harris, K. M. (2002) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00158-3 · Cited by 811 · cited 1×
“Dendritic spine defects are a common feature in AD and human developmental mental retardation syndromes (Fiala et al., 2002).”
BackgroundOxidative stress in the progression of Alzheimer disease in the frontal cortex
Ansari, M. A., & Scheff, S. W. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181cb5af4 · Cited by 605
Increased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405 · cited 1×
“In addition, increased levels of F2-isoprostanes, a marker for lipid peroxidation in the neuronal tissues, have been reported in multiple regions of the brain and cerebrospinal fluid of patients with AD (Praticò et al., 1998; Montine et al., 2005).”
BackgroundGalasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., Jicha, G. A., Cotman, C., Cottrell, B., Montine, T. J., Thomas, R. G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.85 · Cited by 377 · cited 1×
“In respect to this, much attention has been paid to antioxidants as a therapeutic strategy for the treatment of AD (Choi et al., 2012; Feng and Wang, 2012; Galasko et al., 2012; Mecocci and Polidori, 2012).”
BackgroundRho proteins, mental retardation and the cellular basis of cognition
Ramakers, G. J. A. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02118-4 · Cited by 374
Cited by
Anti-inflammatory effects of Rhodiola rosea L.: A review
Pu, W.-L., Zhang, M.-Y., Bai, R.-Y., Sun, L.-K., Li, W.-H., Yu, Y.-L., Zhang, Y., Song, L., Wang, Z.-X., Peng, Y.-F., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109552 · Cited by 227
Panossian, A., Seo, E.-J., & Efferth, T. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.204 · Cited by 127
The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment
Zieneldien, T., Kim, J., & Cao, C. (2022) · Geriatrics · doi:10.3390/geriatrics7020024 · Cited by 29
Metadata
- Authors
- Nabavi, S. F., Braidy, N., Orhan, I. E., Badiee, A., Daglia, M., & Nabavi, S. M.
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2016-01-11
- Volume
- 30
- Issue
- 4
- Pages
- 532-539
- ISSN
- 0951-418X (ISSN-L)
- 1099-1573
- OpenAlex
- W2235660943
- Cited by
- 88
- References
- 15
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rhodiola rosea L. and Alzheimer's Disease: From Farm to Pharmacy. https://app.cochat.ai/papers/10.1002/ptr.5569
- The paper
- Nabavi, S. F., Braidy, N., Orhan, I. E., Badiee, A., Daglia, M., & Nabavi, S. M. (2016). Rhodiola rosea L. and Alzheimer's Disease: From Farm to Pharmacy. Phytotherapy Research. https://doi.org/10.1002/ptr.5569
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.